Inhibition of Myocardin-Related Transcription Factor/Serum Response Factor Signaling Decreases Lung Fibrosis and Promotes Mesenchymal Cell Apoptosis  by Sisson, Thomas H. et al.
The American Journal of Pathology, Vol. 185, No. 4, April 2015ajp.amjpathol.orgSee related Commentary on page 909CELL INJURY, REPAIR, AGING, AND APOPTOSISInhibition of Myocardin-Related Transcription
Factor/Serum Response Factor Signaling Decreases
Lung Fibrosis and Promotes Mesenchymal Cell Apoptosis
Thomas H. Sisson,* Iyabode O. Ajayi,* Natalya Subbotina,* Amos E. Dodi,* Eva S. Rodansky,y Lauren N. Chibucos,*
Kevin K. Kim,* Venkateshwar G. Keshamouni,* Eric S. White,* Yong Zhou,z Peter D.R. Higgins,y Scott D. Larsen,x
Richard R. Neubig,{ and Jeffrey C. Horowitz*From the Division of Pulmonary and Crucial Care Medicine,* Department of Internal Medicine, the Division of Gastroenterology,y Medical School, and the
Vahlteich Medicinal Chemistry Core,x College of Pharmacy, University of Michigan, Ann Arbor, Michigan; the Division of Pulmonary, Allergy, and Critical
Care,z Department of Medicine, University of Alabama, Birmingham, Alabama; and the Department of Pharmacology and Toxicology,{ Michigan State
University, East Lansing, MichiganAccepted for publication(
a
F
K
C
P
hDecember 29, 2014.
Address correspondence to
Jeffrey C. Horowitz, M.D.,
6303 MSRB 3, or Thomas H.
Sisson, M.D., 6300 MSRB 3,
1150 W. Medical Center Dr.,
Ann Arbor, MI 48109-5642.
E-mail: jchorow@umich.edu or
tsisson@med.umich.edu.Supported by NIH/NHLBI grants
K.K.K.), and HL078871 (T.H.S.), NIH
nd R01AR066049 (S.D.L. and R.R.
und for Pulmonary Fibrosis Research
.K.K.).
Portions of this work were present
opyright ª 2015 American Society for Inve
ublished by Elsevier Inc. All rights reserved
ttp://dx.doi.org/10.1016/j.ajpath.2014.12.005Myoﬁbroblasts are crucial to the pathogenesis of tissue ﬁbrosis. Their formation of stress ﬁbers results in
the release of myocardin-related transcription factor (MRTF), a transcriptional coactivator of serum
response factor (SRF). MRTF-A (Mkl1)-deﬁcientmice are protected from lungﬁbrosis.We hypothesized that
the SRF/MRTF pathway inhibitor CCG-203971wouldmodulatemyoﬁbroblast function in vitro and limit lung
ﬁbrosis in vivo. Normal and idiopathic pulmonary ﬁbrosis lung ﬁbroblasts were treated with/without CCG-
203971 (N-[4-chlorophenyl]-1-[3-(2-furanyl)benzoyl]-3-piperidine carboxamide) and/or Fas-activating
antibody in the presence/absence of transforming growth factor (TGF)-b1, and apoptosis was assessed.
In vivo studies examined the effect of therapeutically administered CCG-203971 on lung ﬁbrosis in two
distinct murine models of ﬁbrosis induced by bleomycin or targeted type II alveolar epithelial injury.
In vitro, CCG-203971 prevented nuclear localization of MRTF-A; increased the apoptotic susceptibility of
normal and idiopathic pulmonary ﬁbrosis ﬁbroblasts; blocked TGF-b1einduced myoﬁbroblast differ-
entiation; and inhibited TGF-b1einduced expression of ﬁbronectin, X-linked inhibitor of apoptosis, and
plasminogen activator inhibitor-1. TGF-b1 did not protect ﬁbroblasts or myoﬁbroblasts from apoptosis
in the presence of CCG-203971. In vivo, CCG-203971 signiﬁcantly reduced lung collagen content in both
murine models while decreasing alveolar plasminogen activator inhibitor-1 and promoting myoﬁbro-
blast apoptosis. These data support a central role of the SRF/MRTF pathway in the pathobiology of lung
ﬁbrosis and suggest that its inhibition can help resolve lung ﬁbrosis by promoting ﬁbroblast apoptosis.
(Am J Pathol 2015, 185: 969e986; http://dx.doi.org/10.1016/j.ajpath.2014.12.005)Organ ﬁbrosis is characterized by the accumulation of a
collagen-rich extracellular matrix and the distortion of
normal tissue architecture. This process typically impairs
organ function, and in the lung, derangement of the delicateHL105489 (J.C.H.), HL108904
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.alveolar structure results in signiﬁcant morbidity and mor-
tality.1,2 Although many aspects of the pathogenesis of tissue
ﬁbrosis remain undeﬁned, it is now well accepted that
ﬁbroblasts are important contributors to the production of theInternational Colloquium of Lung and Airway Fibrosis, September
20e24, 2014, Mont Tremblant, QC, Canada.
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Sisson et alexcessive extracellular matrix.3 Furthermore, in the context of
organ ﬁbrosis, ﬁbroblasts consistently differentiate into a
myoﬁbroblast phenotype as deﬁned by the formation of
F-actinecontaining stress ﬁbers and the increased expression
ofa-smoothmuscle actin (SMA).3,4 In addition to the enhanced
production of a-SMA, myoﬁbroblasts elaborate extracellular
matrix proteins, including ﬁbronectin and collagen, and exhibit
an increased resistance to apoptosis.4 In conjunction with their
stress ﬁber formation, myoﬁbroblasts exert contractile forces
on their environment, thereby accentuating the architectural
distortion that is characteristic of tissue ﬁbrosis. Myoﬁbroblast
contractile forces also contribute to the liberation of the proﬁ-
brotic mediator transforming growth factor (TGF)-b1, thereby
exacerbating the ﬁbrotic process.5e8
Because of the crucial role that myoﬁbroblasts play in tissue
ﬁbrosis, substantial effort has been directed toward under-
standing the mechanisms by which these cells undergo dif-
ferentiation from ﬁbroblasts. Through these investigations,
multiple soluble mediators, including TGF-b1, endothelin,
connective tissue growth factor, and lysophosphatidic acid,
have been found to promote the transition.4,9 Beyond soluble
mediators, the presence of a mechanically stiff extracellular
substrate, as measured by resistance to mechanical deforma-
tion, can also stimulate ﬁbroblasts to acquire a myoﬁbroblast
phenotype. Although the induction of ﬁbroblast activation by
a stiff environment is in part due to enhanced TGF-b activa-
tion, recent evidence also indicates that their phenotype is
modiﬁed in response to the rigidity of the substrate to which
the cell is attached via a process ofmechanotransduction that is
independent of enhanced TGF-b activation.8,10
The induction of ﬁbroblast-to-myoﬁbroblast transition,
by either a soluble proﬁbrotic mediator or a stiff extracel-
lular matrix, depends on the activation of intracellular
signaling pathways. The Rho family of GTPases and their
target kinase, Rho-associated kinase (ROCK), were hy-
pothesized to participate in myoﬁbroblast differentiation
and contraction based on the observation that these
signaling molecules are important for actin polymerization,
a crucial element of stress ﬁber formation.9,11e14 Impor-
tantly, recent studies have substantiated a key role for Rho/
ROCK in both soluble mediator and stiff matrix-induced
ﬁbroblast-to-myoﬁbroblast transition. Speciﬁcally, treat-
ment of human lung ﬁbroblasts with an inhibitor of ROCK
signiﬁcantly impeded the TGF-bemediated acquisition of a
myoﬁbroblast phenotype.11,15 Furthermore, the inhibition
of Rho/ROCK signaling disrupted myoﬁbroblast differen-
tiation that was induced when cells were cultured on a
stiff extracellular substrate, and targeting the Rho/ROCK
signaling pathway reduced the severity of ﬁbrosis in an
animal model of lung scarring.13
Besides impairing myoﬁbroblast differentiation through the
disruption of stress ﬁber formation, the targeting of Rho/ROCK
alters the gene expression proﬁle of (myo)ﬁbroblasts.9,14 The
concurrent inhibition of stress ﬁber formation and altered gene
expression implicates a connection between these processes
during myoﬁbroblast differentiation, and myocardin-related970transcription factor (MRTF) has been identiﬁed as a crucial
link.14 MRTF functions as a transcriptional coactivator
that, along with serum response factor (SRF), regulates the
expression of myoﬁbroblast genes, including a-SMA and
collagen.3,9,14 SRF/MRTF signaling is intricately regulated by
actin polymerization; when actin is depolymerized, MRTF is
bound to the globular form and sequestered in the cytoplasm.
During stress ﬁber formation, globular actin polymerizes into
F-actin and releases MRTF, enabling it to translocate into the
nucleus. Both soluble and mechanical stimuli associated with
ﬁbrosis, including TGF-b1 and exposure to stiff substrates,
have been found to promote MRTF nuclear transport in
ﬁbroblasts.9,14,16e19 Furthermore, recent studies showed that
the interruption of SRF/MRTF signaling attenuates myoﬁbro-
blast differentiation and extracellularmatrix synthesis in colonic
ﬁbroblasts and human skin ﬁbroblasts from patients with
scleroderma.16,20
Given the central role of SRF/MRTF signaling in myo-
ﬁbroblast differentiation, we hypothesized that inhibiting
this pathway would prevent myoﬁbroblast activation and
reduce the severity of ﬁbrosis in animal models of lung
injury. To target this signaling pathway, we used a speciﬁc
inhibitor, CCG-203971, a chemically modiﬁed derivative
of CCG-1423, a compound which is known to block the
nuclear localization of MRTF.21 CCG-1423 was initially
identiﬁed by a high-throughput screen to identify small-
molecule inhibitors of the RhoA signaling pathways.22 A
recent report indicates that CCG-1423 binds to the N-ter-
minal basic domain of MRTF, blocks its nuclear localization
signal, prevents its interaction with importin a/b1, and
induces sequestration in the cytoplasm.23 The precise
interactions by which CCG-203971 inhibits SRF/MRTF
have yet to be elucidated, although CCG-100602, another
derivative of CCG-1423, has recently been shown to prevent
the nuclear accumulation of MRTF in colon ﬁbroblasts
exposed to TGF-b1.16,21
Herein, we demonstrate that CCG-203971 inhibits nu-
clear accumulation of MRTF-A in lung ﬁbroblasts, prevents
myoﬁbroblast differentiation, and reduces ﬁbrosis in two
distinct murine models. Moreover, we demonstrate that
blockade of SRF/MRTF signaling affects several proﬁ-
brotic mechanisms, including up-regulation of X-linked
inhibitor of apoptosis (XIAP), ﬁbroblast and myoﬁbroblast
resistance to apoptosis, and expression of plasminogen
activator inhibitor (PAI)-1.
Materials and Methods
Cell Lines and Culture
CCL-210 (normal adult primary human lung) and IMR-
90 (normal primary human fetal lung) ﬁbroblasts were
obtained from ATCC (Manassas, VA). Cells between
passages 8 and 16 were cultured in Dulbecco’s modiﬁed
Eagle’s medium supplemented with 5% fetal bovine
serum, and growth arrested for 16 to 24 hours beforeajp.amjpathol.org - The American Journal of Pathology
Figure 1 CCG-203971 (CCG) inhibits myocardin-related transcription
factor A (MRTF-A) nuclear localization. IMR-90 ﬁbroblasts were cultured on
glass coverslips and treated with/without 2 ng/mL transforming growth
factor (TGF)-b1 and/or 30 mmol/L CCG-203971 for 24 hours. A: The dis-
tribution of MRTF-A was assessed by immunoﬂuorescence staining. B: The
nuclear-to-cytoplasmic ratio of MRTF-A was determined for each condition
as described in Materials and Methods. Data are expressed as means  SEM.
**P < 0.01, ***P < 0.001 versus untreated controls; yyyP < 0.001 versus
TGF-b1treated ﬁbroblasts. Original magniﬁcation, 20 (A).
MRTF in Lung Fibrosis and Fibroblast Apoptosistreatment as previously described.24 Deidentiﬁed normal and
idiopathic pulmonary ﬁbrosis (IPF) lung ﬁbroblasts were
provided by E.S.W. and cultured with the same protocol as
the CCL-210 and IMR-90 ﬁbroblasts, but using 10% fetal
bovine serum. Mkl1 (MRTF-A) knockout murine lung ﬁ-
broblasts were provided by Y.Z. (University of Alabama-
Birmingham, Birmingham, AL),13 These cells were cultured
in minimal essential medium supplemented with 20% fetal
bovine serum.13Becauseof substantial deathwithin 2 to 4 hours
of serum deprivation, treatments were given in media contain-
ing 5% fetal bovine serum. Additionally, these murine cells
demonstrated increased sensitivity to CCG-203971, necessi-
tating a reduction in concentration from 30 to 10 mmol/L.
Antibodies and Reagents
N-(4-chlorophenyl)-1-[3-(2-furanyl)benzoyl]-3-piperidine-
carboxamide (CCG-203971) was synthesized by the Vahl-
teich Medicinal Chemistry Core(University of Michigan,
Ann Arbor, MI) and provided by S.D.L..21 Porcine TGF-b1
was from R&D Systems (Minneapolis, MN). The activating
anti-Fas antibody (clone CH11, designated as Fas-Ab) was
purchased from Millipore (Billerica, MA). Antibodies to
a-SMA and total ﬁbronectin and ﬂuorescein isothiocyanatee
conjugated antiea-SMA antibody were purchased from
Sigma-Aldrich (St. Louis, MO). Antibodies to XIAP,
glyceraldehyde-3-phosphate dehydrogenase, poly-(ADP-
ribose) polymerase (PARP), phosphorylated Smad3, and
total Smad3 were purchased from Cell Signaling (Danvers,
MA). The antibody to MRTF-A was purchased from Santa
Cruz Biotechnology (Dallas, TX). Horseradish peroxidasee
conjugated secondary antibodies were purchased from Pierce
(Rockford, IL). The In Situ Cell Death Detection Kit,
TMR red, was purchased from Roche Life Science (Indi-
anapolis, IN).
Immunoﬂuorescence Staining
IMR-90 cells were cultured and treated in dishes containing
sterilized glass coverslips (Fisher Scientiﬁc, Pittsburgh, PA),
and immunoﬂuorescence staining was performed as previously
described25 using rabbit antieMRTF-A primary antibody
(Santa Cruz Biotechnology, Dallas, TX) at 1:50 dilution and
AlexaFluor 555-conjugated goat anti-rabbit secondary antibody
(Molecular Probes, Eugene, OR) (1:500 dilution). Images were
acquired using an Olympus BX60 microscope with DP72
camera and CellSens Standard imaging software version 1.11
(Olympus America, Center Valley, PA). To quantify the
nuclear-to-cytoplasmic ratio, imageswere imported into ImageJ
software version 1.45s (NIH, Bethesda, MD). Using the Cell-
Mask stain, individual cells were outlined and the optical den-
sity of MRTF-A staining was measured and adjusted for the
area of the cell. Next, the DAPI stain was used to similarly
outline the nucleus and calculate the density of MRTF-A
staining within the nucleus. The cytoplasmic fraction was
determined by subtracting the nuclear fraction from the total cellThe American Journal of Pathology - ajp.amjpathol.orgcalculation, and the nuclear-to-cytoplasmic ratio was deter-
mined by dividing the nuclear signal by the cytoplasmic signal.
Bleomycin Model of Lung Fibrosis
Weight- and age-matched (18 to 22 g at 6 to 8 weeks of age)
C57BL/6 mice were anesthetized with ketamine and xyla-
zine. A 0.5-cm incision was made in the neck to expose the
trachea. Sterile bleomycin [1.2 U/kg in 50 mL of sterile
phosphate-buffered saline (PBS)] was administered intra-
tracheally with a 1.0-mL tuberculin syringe, and the incision
was closed with surgical glue.
Targeted Type II Alveolar Epithelial Cell Injury Model
of Lung Fibrosis
C57BL/6 mice aged 6 to 8 weeks and expressing the human
diphtheria toxin (DT) receptor (DTR) in an alveolar epithelial
cell (AEC)-restricted manner downstream of the surfactant
protein C promoter (SPC-DTRþ) and DTRe (wild-type)
mice were injected with DT 10.0 mg/kg i.p. once daily for 14
days as previously described.26 Control mice were injected
for the same duration with 100 mL of PBS alone.971
Figure 2 Inhibition of serum response factor/myocardin-related tran-
scription factor with CCG-203971 prevents myoﬁbroblast differentiation but
not Smad phosphorylation after treatment with transforming growth factor
(TGF)-b1. Normal adult human lung ﬁbroblasts (CCL-210) were cultured to
60% conﬂuence in Dulbecco’s modiﬁed Eagle’s medium (DMEM) supple-
mented with 5% fetal bovine serum and growth arrested in serum-free
DMEM for 24 hours. Cells were treated with 0, 0.3, 3.0, or 30 mmol/L
CCG-203971 for 30 minutes before treatment with/without 2 ng/mL TGF-b1
or with 30 mmol/L CCG-203970 in the absence of TGF-b1. A: Whole-cell
lysates were obtained after 24 hours, and a-smooth muscle actin (SMA)
expression was determined by Western blot analysis. Blots were stripped
and probed for glyceraldehyde-3-phosphate dehydrogenase (GAPDH). B:
For each Western blot, the density of the a-SMA band and the corre-
sponding GAPDH band were measured with ImageJ version 1.45s (NIH,
Bethesda, MD). The ratio of a-SMA to GAPDH was determined for each
condition, and then normalized so that the ratio in untreated cells was
equivalent to 1.0. Pooled analysis from at least three independent exper-
iments with each concentration of CCG-203971 is shown. C: CCL-210 ﬁ-
broblasts were treated with or without 2 ng/mL TGF-b1 in the presence or
absence of 30 mmol/L CCG-203971 for 30 and 60 minutes. Whole-cell ly-
sates were assessed for Smad3 phosphorylation by Western blot analysis,
and blots were stripped and reprobed for total Smad3. Data are expressed
as means  SEM. **P < 0.01 versus untreated controls; yP < 0.05 versus
TGF- b1 treatment in the absence of CCG-203971.
Sisson et alIn Vivo CCG-203971 Treatment
For both the bleomycin and targeted type II AEC injury
models, 100 mg/kg of CCG-203971 dissolved in 50 mL of
dimethyl sulfoxide (DMSO) was administered b.i.d. by i.p.
injection20 beginning on day 11 of each model. Control972mice received 50 mL of DMSO vehicle b.i.d. beginning at
the same time point.
TUNEL Staining
Lungs were perfused with PBS, inﬂated with intratracheal
OCT, removed, and immediately frozen in a dry-ice alcohol
bath and stored at 80C. Lung sections (7 mm) were ﬁxed,
mounted with ProLong Gold Antifade Mountant with DAPI
(Life Technologies, Carlsbad, CA), permeabilized, and
immunostained as previously described.27 Terminal deoxy-
nucleotidyl transferase dUTP nick end labeling (TUNEL)
staining was performed with the In Situ Cell Death Detection
Kit, TMR Red, per the manufacturer’s instruction manual.
Fluorescein isothiocyanateeconjugated a-SMA staining was
performed with a 1:200 dilution. Sections were visualized
on an Olympus BX-51 ﬂuorescence microscope and im-
ages were captured with an Olympus DP-70 camera and
analyzed using DP controller software version 3.1.1.267.
Numbers of TUNEL-positive cells were quantiﬁed from
ten 400 ﬁelds for each mouse by an observer blinded to
the treatment group (K.K.K.).
Lung Histological Examination and Picrosirius Red
Stain
After perfusion of the pulmonary vasculature with PBS, the
left lung was inﬂation-ﬁxed at 25 cm H2O pressure with
10% neutral-buffered formalin, removed en bloc, further
ﬁxed in 10% neutral-buffered formalin overnight, and then
parafﬁn-embedded. Five-micron sections were then stained
using hematoxylin and eosin or picrosirius red.28
Hydroxyproline Assay
The hydroxyproline concentration was measured in both
lungs as previously described.28
Western Immunoblot Analysis and Densitometry
Whole-cell lysates were collected and subjected to SDS-PAGE
and Western blot analysis as previously described.24 All
Western blots were stripped and reprobed for glyceraldehyde-3-
phosphate dehydrogenase or, in the case of phosphorylated
Smad3, for total Smad3. Densitometry and quantiﬁcation of
Western blots were performed with ImageJ software version
1.45s as previously detailed.24
Assessment of Apoptosis
CleavedPARPwasassessedviaWesternblot analysis.Histone-
associated DNA fragments were detected using the Cell Death
Detection enzyme-linked immunosorbent assay (ELISA) kit
(Roche Applied Science, Indianapolis, IN) according to the
manufacturer’s instructions. Kinetic assessments of apoptosis
were made by the analysis of caspase-3/7 activation usingajp.amjpathol.org - The American Journal of Pathology
Figure 3 CCG-203971 blocks basal and transforming growth factor
(TGF)-b1 induced ﬁbronectin expression with or without 2 ng/mL TGF-b1 in
the presence or absence of 30 mmol/L CCG-203971 for 30 and 60 minutes.
A: Total ﬁbronectin expression was determined by Western blot analysis.
Each blot was stripped and probed for glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH). B: Fibronectin-to-GAPDH ratios were determined and
normalized to the ratio observed in untreated cells. Data presented are a
pooled analysis that includes a minimum of three experiments with each
concentration of CCG-203971. Data are expressed as means  SEM.
***P < 0.001 versus untreated controls; yyyP < 0.001 versus cells treated
with TGF-b1 alone.
MRTF in Lung Fibrosis and Fibroblast Apoptosisﬂuorescence imaging. For this assay, lung ﬁbroblasts were
seeded into a 6- or 24-well plate and cultured to approximately
50% to 60% conﬂuence. After 16 hours of serum deprivation,
cells were washed with PBS and placed in serum-free media
containing 500 mL of CellPlayer 96-well kinetic caspase-3/7
reagent (Essen BioScience, Ann Arbor, MI) at a ﬁnal concen-
tration of 0.5mmol/L. The activation of caspase-3/7, amarker of
apoptosis, resulted in green ﬂuorescence staining of nuclear
DNA. Using an IncuCyte system (Essen BioScience), time-
lapsed imageswere obtainedwith20magniﬁcation fromnine
spotswithin eachwell of a 24-well plate or 16 spots perwell in a
6-well plate every 2 hours.29 IncuCyte software version 2011A
(Essen Bioscience, Ann Arbor MI) was used to quantify the
ﬂuorescent signal, which is represented as the object count per
image.
PAI-1 Measurement
Endogenous total and/or active murine PAI-1 concentrations
were measured in bronchoalveolar lavage ﬂuid and cell cultureThe American Journal of Pathology - ajp.amjpathol.orgsupernatants using a carboxylated microsphereebased ELISA
as previously described.30
Statistical Analysis
Comparisons were made with either analysis of variance
with multiple comparisons post-test or, when comparing
multiple variables over time, 2-way analysis of variance
with multiple comparisons using GraphPad Prism version
6.01 (GraphPad Software, Inc., San Diego, CA).
Results
CCG-203971 Inhibits MRTF-A Nuclear Localization and
Impairs TGF-b1eInduced Myoﬁbroblast Differentiation
and Fibronectin Deposition
Prior studies have implicated Rho and SRF/MRTF-mediated
signaling pathways in ﬁbroblast differentiation and collagen
production.13,15,16,20,31 To examine the effect of a novel
speciﬁc inhibitor of this pathway, CCG-203971, on TGF-
b1einduced normal lung ﬁbroblast differentiation and acti-
vation, we examined nuclear localization of MRTF-A in
normal lung ﬁbroblasts (Figure 1). IMR-90 ﬁbroblasts
cultured on glass coverslips were treated with/without TGF-
b1 and/or CCG-203971 for 24 hours. The distribution of
MRTF-A was assessed by immunoﬂuorescence staining
(Figure 1A), and the nuclear-to-cytoplasmic ratio was quan-
tiﬁed (Figure 1B). CCG-203971, in the presence or absence of
TGF-b1, led to a signiﬁcant reduction in MRTF-A nuclear
localization.
Because nuclear localization of MRTF-A has been shown
to be crucial for myoﬁbroblast differentiation, we did a
concentrationeresponse analysis of a-SMA expression after
TGF-b1 treatment in the presence/absence of CCG-203971.
CCL-210 ﬁbroblasts were exposed to 0.3, 3.0, or 30 mmol/L
CCG-203971 30 minutes before TGF-b1 exposure, and
a-SMA was assessed at 24 hours via Western blot analysis
(Figure 2, A and B). The reported IC50 for CCG-203971
ranges from 4.2 to 6.2 mmol/L,16,21 and we observed
signiﬁcant suppression of TGF-b1emediated a-SMA
expression at the 30 mmol/L concentration (approximately
sixfold the IC50). No effect was seen with the 0.3 or 3.0
mmol/L concentrations. These ﬁndings are concordant
with recent ﬁndings in human colonic ﬁbroblasts and in
normal and scleroderma-associated skin ﬁbroblasts.16,20
To ensure that the inhibition of myoﬁbroblast differenti-
ation was not due to nonspeciﬁc blockade of proximal
TGF-b1 signaling, we treated ﬁbroblasts with/without
CCG-203971 followed by TGF-b1 and assessed for Smad
activation (Figure 2C). Pretreatment with CCG-203971
had no impact on the rapid and robust phosphorylation
of Smad3 by TGF-b1.
Rho- and SRF/MRTF-mediated signaling regulates
collagen synthesis by ﬁbroblasts.16,20 Aside from collagen,
the extracellular matrix component ﬁbronectin is a crucial973
Figure 4 CCG-203971 (CCG) reduces lung ﬁbrosis after intratracheal bleomycin (bleo). Wild-type C57BL/6 mice were treated with 1.2 U/kg intratracheal
bleomycin or phosphate-buffered saline (PBS) as previously described.30 Starting on day 11 after bleomycin administration, the mice received CCG-203971
(100 mg/kg b.i.d. via i.p. injection) or an equal volume of vehicle control (dimethyl sulfoxide; DMSO). A: Weight changes over time. Weights were ob-
tained on days 4, 6, and 8 before the administration of CCG-203971 and then daily through day 20 after the initiation of CCG-203971 administration.
B: Hydroxyproline concentrations of both lungs at day 21 after bleomycin administration. Two independent experiments were completed with similar results,
and the ﬁgure shown represents one of the experimental replicates. C: Representative histological examination. D: Representative picrosirius red staining.
Data are expressed as means  SEM. nZ 7 mice per group (A and B). *P < 0.05, **P < 0.01, bleomycin/CCG-203971 and bleomycin/DMSO versus PBS/CCG-
203971 and PBS/DMSO; yyP < 0.01, PBS/CCG-203971 and PBS/DMSO versus bleomycin/DMSO; zP < 0.05, bleomycin/CCG-203971 versus bleomycin/DMSO;
xxxxP < 0.0001 versus untreated controls and CCG-203971 alone; {{{{P < 0.0001 versus bleomycin-treated mice.
Sisson et almediator of ﬁbroblast phenotype and function, including
differentiation and survival.14,32 Accordingly, we sought to
determine the impact of inhibiting this pathway on TGF-
b1emediated ﬁbronectin accumulation. As with a-SMA
expression, we found that 30 mmol/L of CCG-203971
completely abrogated TGF-b1einduced ﬁbronectin depo-
sition at 24 hours in CCL-210 ﬁbroblasts (Figure 3). In974contrast to a-SMA, basal expression of total ﬁbronectin (in
the absence of TGF-b1) was also markedly suppressed by
CCG-203971. The inhibitory effects of CCG-203971 on the
TGF-b1 induction of a-SMA and ﬁbronectin expression
were maintained at 48 hours (data not shown), and similar
results were obtained in a second line of normal (fetal)
human lung ﬁbroblasts (IMR-90) (data not shown).ajp.amjpathol.org - The American Journal of Pathology
Figure 5 CCG-203971 (CCG) attenuates lung ﬁbrosis after type II alveolar epithelial injury. Surfactant protein C promoterediphtheria toxin receptor (SPC-
DTRþ) and DTR transgenic mice were injected with/without 10.0 mg/kg diphtheria toxin (DT) i.p. once daily for 14 days. CCG-203971 100 mg/kg i.p. b.i.d.
was administered from day 11 to 21 in the indicated groups. A: Weights were obtained at the indicated time points. CCG-203971 treatment alone did not lead
to any weight loss in the DTRþ mice that did not receive DT (data not shown). B: At day 21, both lungs from at least ﬁve mice per group were assessed for
hydroxyproline. The experiment was performed twice, with similar results. C: Representative histological examination and picrosirius red staining from
additional mice at day 21. Insets represent digital enlargements of the indicated areas of the corresponding 40 image. Data are expressed as means  SEM
(A and B). nZ 5 to 7 per group (A and B). *P < 0.05, **P < 0.01 versus DTR mice treated with DT alone; yP < 0.05 versus DTR controls without DT treatment;
zzP < 0.01 versus DTR mice treated with DT and CCG-203971. H&E, hematoxylin and eosin. DMSO, dimethyl sulfoxide.
MRTF in Lung Fibrosis and Fibroblast ApoptosisPostinﬂammatory Administration of CCG-203971
Attenuates Lung Fibrosis
Several studies have shown that strategies targeting myoﬁ-
broblast phenotypes can decrease lung ﬁbrosis.33e35 To
determine whether pharmacological therapy directly targeting
SRF/MRTF signaling also reduces lung ﬁbrosis, we treated
wild-type C57BL/6 mice with either CCG-203971 or vehicleThe American Journal of Pathology - ajp.amjpathol.orgcontrol between days 11 and 21 after the administration of
intratracheal bleomycin and assessed the impact of this com-
pound during the postinﬂammatory phase of this model of
lung injury and ﬁbrosis (Figure 4).36,37 Mice receiving intra-
tracheal bleomycin exhibited weight loss that was evident at
day 3 and statistically signiﬁcant by day 6, whereas the
uninjured control mice receiving CCG-203971 did not
demonstrate weight loss (Figure 4A). After day 11, the cohort975
Figure 6 Fas-mediated apoptosis is enhanced by CCG-203971 (CCG) in IMR-90 ﬁbroblasts. IMR-90 ﬁbroblasts were treated with 0.3, 3.0, or 30 mmol/L CCG-
203971 alone or in combination with 250 ng/mL Fas-activating antibody (Fas-Ab). A: Apoptosis was assessed by the detection of a green-ﬂuorescent signal
indicating cleavage by caspase-3/7 and quantiﬁed at the indicated time points using IncuCyte software version 2011A as described in Materials and Methods.
B: Cells were treated with 250 ng/mL Fas-Ab, 30 mmol/L CCG-203971, or the combination, and apoptosis was similarly assessed at baseline and 16 hours. C and
D: IMR-90 ﬁbroblasts were treated with 250 ng/mL Fas-Ab and/or 0, 3.0, or 30 mmol/L CCG-203971 for 8 hours (C) or 16 hours (D). Apoptosis was assessed by
Western blot analysis for cleaved poly-(ADP-ribose) polymerase (PARP); blots were stripped and probed for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). E: Similarly, IMR-90 ﬁbroblasts were treated with Fas-Ab and/or 30 mmol/L CCG-203971 for 8 or 16 hours, and apoptosis was assessed by enzyme-
linked immunosorbent assay detection of histone-associated DNA fragments. Data are expressed as means  SEM. Each data point represents three replicates,
with each replicate comprised of nine different images from each well at each time point (A and B). n Z 3 at each time point for each condition (E).
*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 versus control; yP < 0.05 versus baseline controls; zzzP < 0.001 versus Fas-Ab alone and CCG-
203971 at 16 hours; xxP < 0.01 versus Fas-Ab þ CCG-203971 at 8 hours.
Sisson et alof bleomycin-treated mice that received CCG-203971 had a
signiﬁcant reversal of weight loss, whereas the mice that
received vehicle control continued to lose weight. By day 14,
there was a statistically signiﬁcant difference in weight between
the bleomycin/CCG-203971 and bleomycin/DMSO groups.
By day 20, there were no signiﬁcant differences between the
bleomycin/CCG-203971 cohort and the uninjured/DMSO
and uninjured/CCG-203971 groups. Importantly, mice
receiving CCG-203971 in the absence of bleomycin-
induced lung injury did not exhibit any weight loss, and
their weights over the course of the experiment were no
different from those in the uninjured mice receiving
vehicle control.
Lung hydroxyproline was quantiﬁed at day 21 as a
measure of lung collagen content.36 In mice that received
intratracheal bleomycin with vehicle control, there was a
signiﬁcant increase in lung hydroxyproline content, which
was markedly attenuated in the bleomycin-injured cohort
that received CCG-203971 between days 11 and 21
(Figure 4B). Evaluation of hematoxylin and eosin stained
lung sections from this same time point demonstrated976extensive zones of lung ﬁbrosis, including increased cellu-
larity and matrix accumulation in the bleomycin-injured
mice, which were markedly reduced in mice treated
with CCG-203971 (Figure 4C). Consistently, CCG-203971
signiﬁcantly reduced collagen accumulation as observed
with picrosirius red staining (Figure 4D).
We used the targeted type II AEC injury model to investigate
the efﬁcacy of CCG-203971 in a secondmodel of ﬁbrosis that is
not dependent on acute lung injuryeinduced inﬂammation
(Figure 5).26,28,36 Therapeutic administration of CCG-203971
between days 11 and 21 was associated with an observable,
but not statistically signiﬁcant, improvement in the weight of
SPC-DTRþmice (Figure 5A). Control mice (SPC-DTRþmice
that did not receive DT) treated with CCG-203971 did not
experience weight loss compared with untreated controls (data
not shown). The therapeutic administration of CCG-203971 to
DT-treated SPC-DTRþ mice was associated with a signiﬁcant
reduction in lung ﬁbrosis as assessed by collagen accumulation
(hydroxyproline quantiﬁcation and picrosirius red staining)
(Figure 5, B and C) and histological examination (Figure 5C).
Thus, in complementary models of lung ﬁbrosis, we found thatajp.amjpathol.org - The American Journal of Pathology
Figure 7 Inhibition of serum response factor/myocardin-related transcription factor A (MRTF-A) signaling by CCG-203971 and MRTF-A deﬁciency promotes Fas-
mediated apoptosis in ﬁbroblasts. CCL-210 ﬁbroblasts were exposed to 250 ng/mL Fas-activating antibody (Fas-Ab) with or without 0, 3.0, or 30mmol/L CCG-203971 for
8 hours. A: Apoptosis was assessed by Western blot analysis for cleaved poly-(ADP-ribose) polymerase (PARP). Blots were stripped and probed for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). B: Relative densitometry was based on the ratio of cleaved PARP to GAPDH for each condition. C: Apoptosis in CCL-210 ﬁbroblasts
was assessed by enzyme-linked immunosorbent assay (ELISA) detection of histone-associated DNA fragments. D: Lung ﬁbroblasts from wild-type (WT) mice and
transgenic mice deﬁcient in MRTF-A (Mkl1) were treated with 250 ng/mL Fas-activating antibody (Fas-Ab), and apoptosis was assessed at 8 hours by detection of
histone-associated DNA fragments. E: Normal primary adult lung ﬁbroblasts (left graph) and ﬁbroblasts from the lungs of patients with idiopathic pulmonary ﬁbrosis
(IPF; right graph) were treated with/without 250 ng/mL Fas-Ab and/or 30mmol/L CCG-203971, and apoptosis was assessed after 8 hours by ELISA detection of histone-
associated DNA fragments. Data are expressed as means SEM. nZ 3 or more replicates per condition (B); nZ 3 per group (C); nZ 3, WT, and nZ 6, Mkl/ (D);
nZ 4 normal and 4 IPF cell lines (E). **P< 0.01 versus untreated control; yP< 0.05 versus Fas-Ab alone, CCG-203971 alone, and CCG-203971 3mmol/Lþ Fas-Ab; zP<
0.05, zzP < 0.01 versus untreated control; xP < 0.05 versus WT and Mkl1/ control and WT ﬁbroblasts treated with Fas-Ab.
MRTF in Lung Fibrosis and Fibroblast Apoptosisthe therapeutic administration of CCG-203971 signiﬁcantly
limited the extent of lung ﬁbrosis.
Inhibition of SRF/MRTF Signaling with CCG-203971
Enhances Fibroblast Susceptibility to Apoptosis
Myoﬁbroblast apoptosis is a crucial component of the reso-
lution phase of normal wound repair, and our recent studies
have shown that blockade of antiapoptotic signaling path-
ways can enhance myoﬁbroblast susceptibility to
apoptosis.3,24,36e41 To determine how blockade of SRF/
MRTF-mediated signaling by CCG-203971 affected myoﬁ-
broblast susceptibility to apoptosis, we ﬁrst measured
apoptosis induction over time in IMR-90 ﬁbroblasts
treated with/without Fas-Ab in the presence or absence of
different concentrations of CCG-203971, using image-based
quantiﬁcation of caspase-3/7 activation (Figure 6A). Over the
initial 9 hours, there was no signiﬁcant apoptosis observed in
the untreated IMR-90 ﬁbroblasts, whereas cells treated with
Fas-Ab showed amild increase in apoptosis that did not reach
statistical signiﬁcance (means SEM, 11.4 0.7 counts per
image at baseline compared with 23.2 0.7 counts per imageThe American Journal of Pathology - ajp.amjpathol.orgat 9 hours). IMR-90 ﬁbroblasts treated with the Fas-Ab in the
presence of 30 mmol/L CCG-203971, in contrast, showed a
signiﬁcantly increased rate of apoptosis that was evident at 5
hours (2.3-fold increase, from 11.5 0.7 to 26.6 1.4 counts
per image; P< 0.01) and progressed to a 4.7-fold increase by
9 hours (53.6  9.7 counts per image; P < 0.0001).
We have previously shown that Fas-Ab induce a modest,
but signiﬁcant, increase in the apoptosis of IMR-90 ﬁbro-
blasts after 16 hours of treatment.36 Consistent with these
previous results, we observed a 3.2-fold increase in apoptosis
at 16 hours in these cells after treatment with the Fas-Ab
(P < 0.01) (Figure 6B). Notably, at the 16-hour time point,
treatment with 30 mmol/L of CCG-203971 alone induced a
threefold increase in apoptosis compared with baseline
(P < 0.05), which was not signiﬁcantly different from that
with the Fas-Ab alone. Compared with either CCG-203971
or Fas-Ab exposure alone, the combination of Fas-Ab with
30 mmol/L CCG-203971 induced an additional 2.5-fold in-
crease in apoptosis at the 16-hour time point (P < 0.001 for
each comparison).
To conﬁrm the results of the automated quantiﬁcation of
caspase-3/7 activation method, two additional apoptosis977
Figure 8 Transforminggrowth factor (TGF)-b1 fails to reduce Fas-mediated
apoptosis in IMR-90 ﬁbroblasts treated with CCG-203971. IMR-90 ﬁbroblasts
were cotreated with 250 ng/mL Fas-activating antibody (Fas-Ab) with/without
30 mmol/L CCG-203971 and/or 2 ng/mL TGF-b1 for 8 hours. Apoptosis was
assessed by Western blot analysis for cleaved poly-(ADP-ribose) polymerase
(PARP) (A) with densitometry (B) and by enzyme-linked immunosorbent assay
for histone associated DNA fragments (C). Data are expressed as means SEM.
nZ 2 per condition (B and C). *P< 0.05 versus controls, TGF-b1 alone, Fas-Ab
alone, and Fas-Ab þ TGF-b1; yP < 0.05 versus Fas-Ab þ CCG-203971, with or
without TGF- b1; zP< 0.05 versus all groups that did not receive Fas-Abþ CCG-
203971. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Sisson et alassessments were performed. First, IMR-90 ﬁbroblasts were
treated with/without the Fas-Ab in the presence or absence
of CCG-203971 at concentrations of 3.0 or 30.0 mmol/L for
8 hours (Figure 6C) or 16 hours (Figure 6D), and apoptosis
was assessed by Western blot for cleaved PARP. Consistent
with the results from the ﬂuorescent imaging assay, at 8
hours, cells treated with the Fas-Ab combined with 30
mmol/L CCG-203971 exhibited a clear increase in the
cleaved PARP band, indicative of apoptosis. At this early
time point, treatment with the Fas-Ab alone or with either
3.0 or 30 mmol/L of CCG-203971 alone did not induce an
increase in cleaved PARP, and these results were consistent
with those from the imaging assay. A slight increase in
cleaved PARP was seen in cells treated with the combina-
tion of 3.0 mmol/L CCG-203971 and the Fas-Ab. At 16978hours, there was a signiﬁcant increase in the cleaved PARP
band from cells treated with the Fas-Ab alone and from cells
treated with the Fas-Ab combined with 30 mmol/L CCG-
203971. Along with the increase in cleaved PARP, there
was a marked reduction in the intact PARP band in cells
treated with the combination of Fas-Ab and 30 mmol/L CCG-
203971, indicative of the advanced stage of apoptosis.42,43
Because PARP cleavage is dependent on activated
caspase-3, we used an additional nonecaspase-based tech-
nique to further assess apoptosis. With an ELISA-based
assay to detect histone-associated DNA fragments, we again
found that the 30 mmol/L concentration of CCG-203971 in
combination with a Fas-Ab induced a signiﬁcant increase in
apoptosis at 8 hours, which was further accentuated at 16
hours (Figure 6E).
To demonstrate that the increased susceptibility to Fas-
mediated apoptosis induced by CCG-203971 was not
limited to normal fetal lung ﬁbroblasts, we performed a
complementary set of experiments in CCL-210 (normal
human adult) lung ﬁbroblasts (Figure 7, AeC). As in the
IMR-90 ﬁbroblasts, treatment of CCL-210 ﬁbroblasts with
the combination of Fas-Ab and 30 mmol/L CCG-203971
induced apoptosis at 8 hours, as assessed by Western blot
analysis for cleaved PARP (Figure 7, A and B) and by
ELISA detection of histone-associated DNA fragments
(Figure 7C). At 16 hours of treatment, there was extensive
death of CCL-210 ﬁbroblasts after treatment with the
combination of Fas-Ab and 30 mmol/L CCG-203971, such
that no cleaved or intact PARP was detected by Western
blot analysis, precluding quantiﬁcation (data not shown).
Next, we examined the apoptotic susceptibility of lung
ﬁbroblasts from transgenic Mkl1 (the mouse orthologue of
MRTF-A) knockout mice and found that, in contrast to
normal lung ﬁbroblasts, the cells lacking MRTF-A had a
robust apoptotic response to treatment with Fas-Ab
(Figure 7D), providing further evidence that MRTF-A
signaling participates in the apoptosis-resistant pheno-
type of lung ﬁbroblasts. Combined treatment with Fas-Ab
and CCG-203971 did not lead to a further increase in
apoptosis in the MRTF-Aedeﬁcient ﬁbroblasts (data not
shown), suggesting that the CCG-203971emediated increase
in ﬁbroblast susceptibility to Fas-mediated apoptosis is un-
likely to represent an off-target effect of the drug.
Previous studies from our laboratory have shown that
inhibition of survival signaling pathways can restore the
apoptotic susceptibility of ﬁbrotic lung ﬁbroblasts.36,41 To
determine whether CCG-203971 similarly sensitized ﬁbrotic
lung ﬁbroblasts to apoptosis, normal and IPF lung ﬁbro-
blasts (n Z 4 of each) were treated with Fas-Ab in the
presence or absence of CCG-203971, and apoptosis was
assessed after 8 hours (Figure 7E). Fas activation did not
lead to a signiﬁcant increase in apoptosis in either cohort of
lung ﬁbroblasts at this time point, but the addition of CCG-
203971 signiﬁcantly enhanced Fas-mediated apoptosis.
These data suggest that the role of SRF/MRTF signaling in
ﬁbroblast resistance to apoptosis is not limited to cell linesajp.amjpathol.org - The American Journal of Pathology
Figure 9 Transforming growth factor (TGF)-b1 does not rescue CCL-210 ﬁbroblasts from Fas-mediated apoptosis in the presence of CCG-203971 (CCG). CCL-
210 ﬁbroblasts were treated with 250 ng/mL Fas-activating antibody (Fas-Ab) with/without 30 mmol/L CCG-203971 and/or 2 ng/mL TGF-b1 for 8 hours.
Apoptosis was assessed by Western blot analysis for cleaved poly-(ADP-ribose) polymerase (PARP) (A) with quantiﬁcation by densitometry (B), enzyme-linked
immunosorbent assay for histone associated DNA fragments (C), and cleavage of a ﬂuorescent substrate by activated caspase-3/7 with image analysis at
2-hour intervals and quantiﬁcation of the ﬂuorescent signal using the IncuCyte software version 2011A, 20 magniﬁcation (D). E: Representative images of
each condition at baseline and after 10 hours. Data are expressed as means  SEM. nZ 2 per group (B); nZ 3 per group (C); nZ 2 with 16 independent
images per replicate analyzed at each time point (D) (the detail of this analysis is given in Materials and Methods). ***P < 0.001 versus control, TGF-b1 alone,
Fas-Ab alone, and Fas-Ab þ CCG-203971; yP < 0.05 versus Fas-Ab þ CCG-203971 with or without TGF-b1; zP < 0.05 versus control, Fas-Ab alone, CCG-203971
alone, and Fas-Ab þ TGF-b1; xP < 0.05, xxP < 0.01 versus control and CCG-203971 alone. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
MRTF in Lung Fibrosis and Fibroblast Apoptosisand that regulation of SRF/MRTF signaling is sufﬁcient to
modulate apoptotic susceptibility in ﬁbrotic lung ﬁbroblasts.
TGF-b1 Does Not Confer Protection from Apoptosis
Induced by Fas Activation in the Presence of
CCG-203971
Among the multitude of proﬁbrotic activities of TGF-b1, we
have shown that TGF-b1 promotes ﬁbroblast resistance toThe American Journal of Pathology - ajp.amjpathol.orgapoptosis through different mechanisms, including the
induction of XIAP, survivin, and PAI-1 expression.36,40,41
To determine whether TGF-b1 could reverse the increased
susceptibility to Fas-mediated apoptosis in normal lung
ﬁbroblasts exposed to CCG-203971, IMR-90 ﬁbroblasts
(Figure 8) and CCL-210 ﬁbroblasts (Figure 9) were treated
with Fas-activating antibodies in the presence/absence of 30
mmol/L CCG-203971 and/or 2 ng/mL TGF-b1. In each
normal lung ﬁbroblast cell line across multiple apoptosis979
Figure 10 CCG-203971 sensitizes differentiated myoﬁbroblasts to
Fas-mediated apoptosis. CCL-210 ﬁbroblasts were treated with/without
2 ng/mL transforming growth factor (TGF)-b1 for 24 hours and then treated
with/without 250 ng/mL Fas-activating antibody (Fas-Ab) and/or 30
mmol/L CCG-203971. Apoptosis was assessed by Western blot analysis for
poly-(ADP-ribose) polymerase (PARP) (A) and cleavage of a ﬂuorescence
substrate by activated caspase-3/7 with image analysis at 8 hours (B). Data
are expressed as means  SEM. nZ 3 replicates of each condition with 16
separate images of each replicate analyzed. **P < 0.01, ***P < 0.001
versus control; yyyP < 0.001 versus Fas-Ab þ CCG-203971. GAPDH, glyc-
eraldehyde-3-phosphate dehydrogenase.
Sisson et alassays, we found that TGF-b1 cotreatment had no signiﬁ-
cant impact on ﬁbroblast susceptibility to Fas-mediated
apoptosis in the presence of CCG-203971, indicating that
the apoptosis-resistant ﬁbroblast phenotype induced by
TGF-b1 requires intact SRF/MRTF signaling.
Having shown that TGF-b1 cotreatment did not protect
ﬁbroblasts from Fas-mediated apoptosis when SRF/MRTF
signaling was blocked by CCG-203971, we next assessed the
impact of CCG-203971 on the apoptosis susceptibility of fully
differentiated myoﬁbroblasts (Figure 10). CCL-210 ﬁbroblasts
were treated with/without TGF-b1 for 24 hours before treat-
ment with Fas-Ab and/or CCG-203971 for 8 hours, and
apoptosis was assessed by Western blot analysis for cleaved
PARP (Figure 10A) and by cleavage of a ﬂuorogenic substrate
of caspase-3/7 (Figure 10B). Fas-Ab induced a small increase in
cleaved PARP in ﬁbroblasts, which was not seen in the TGF-b1
pretreated myoﬁbroblasts. With image-based quantiﬁcation,
there was no statistically signiﬁcant difference in apoptosis with
Fas-treatment alone in either population of cells at the 8-hour
time point. No apoptosis was seen in cells treated with CCG-
203971 alone. In both ﬁbroblasts and myoﬁbroblasts, the
combination of Fas-Ab and CCG-203971 was sufﬁcient to
induce robust apoptosis. Interestingly, differentiated myoﬁ-
broblasts (pretreated with TGF-b1) demonstrated markedly
increased apoptosis when treated with the combination; this
ﬁnding was most evident using the image-based quantiﬁcation980of ﬂuorogenic substrate, although a similar pattern of accentu-
ated apoptosis in the myoﬁbroblasts was also demonstrated by
increased cleaved PARP along with decreased intact PARP
(Figure 10A). These data indicate that CCG-203971 enhances
Fas-mediated apoptosis in ﬁbroblasts, regardless of state of
differentiation.
CCG-203971 Decreases TGF-b1 Induction of XIAP
To further examine the mechanisms by which the inhibition of
SRF/MRTF signaling might enhance ﬁbroblast susceptibility
to apoptosis, we next assessed the effect of CCG-203971 on
XIAP expression. We have shown that XIAP is induced by
TGF-b1 in normal lung ﬁbroblasts and serves to protect ﬁbro-
blasts from Fas-mediated apoptosis.36 TGF-b1 treatment of
CCL-210ﬁbroblasts thatwere exposed toCCG-203971at doses
that enhance ﬁbroblast susceptibility to apoptosis did not result
in an increase in XIAP (Figure 11, A and B), demonstrating that
this inhibitor of apoptosis protein is regulatedby theSRF/MRTF
pathway.
Targeting the SRF/MRTF Pathway with CCG-203971
Decreases PAI-1 Expression by Fibroblasts
As another potential mechanism by which SRF/MRTF pro-
motes ﬁbrosis, we examined the participation of this signaling
pathway in TGF-b1einduced ﬁbroblast-mediated expression
of the proﬁbrotic molecule PAI-1. In this experiment, CCL-
210 cells were treated with TGF-b1 in the presence or absence
of 30 mmol/L CCG-203971. Consistent with ﬁndings from
prior reports,40 TGF-b1 markedly increased the levels of total
and active PAI-1 in the conditioned media of the ﬁbroblast
cultures at 24 hours (Figure 11, C and D). This increase in
PAI-1 was signiﬁcantly attenuated by the inhibition of the
SRF/MRTF pathway.
Enhanced Fibroblast Apoptosis and Suppressed PAI-1
Expression in Vivo after the Administration of
CCG-203971
Wild-type C57BL/6 mice were injured with intratracheal
bleomycin for the examination of the mechanisms by which
SRF/MRTFblockade reducedﬁbrosis in vivo. Onday 11,CCG-
203971 or DMSO treatment was initiated in subgroups of ani-
mals. On day 14, a time point at which we had observed an
improvement in weight loss with drug treatment (Figure 4A),
lungs were harvested for immunostaining of TUNEL as an in-
dicator of apoptosis, and bronchoalveolar lavage ﬂuid was
collected for the quantiﬁcation of PAI-1 levels. The inhibition of
SRF/MRTF signaling with CCG-203971 resulted in a signiﬁ-
cant increase in the number of TUNEL-positive cells compared
with that in the vehicle-treated control group (Figure 12, AeD).
Having identiﬁed an increase in the number of TUNEL-positive
cells in the lungs of mice treated with bleomycin and CCG-
203971, we performed immunoﬂuorescence colocalization
with TUNEL and a-SMA as a qualitative assessment of whichajp.amjpathol.org - The American Journal of Pathology
Figure 11 Inhibition of serum response factor/myocardin-related transcription factor with CCG-203971 prevents transforming growth factor (TGF)-b1 in-
duction of X-linked inhibitor of apoptosis (XIAP) and secretion of plasminogen activator inhibitor (PAI)-1. CCL-210 ﬁbroblasts were treated with 2 ng/mL TGF-b1
in the presence/absence of CCG-203971 (indicated doses) for 24 hours. Whole-cell lysates were assessed for XIAP expression by Western blot analysis (A) with
densitometric analysis (B). Cell culture supernatants were assessed for total (C) and active (D) PAI-1. Data are expressed as means  SEM. n Z at least 3
replicates per condition (B); nZ 3 for CCG-203971 alone and 12 for all other conditions (C and D). *P < 0.05, ****P < 0.0001 versus control; yyP < 0.01,
yyyyP < 0.0001 versus TGF-b1. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
MRTF in Lung Fibrosis and Fibroblast Apoptosiscells were undergoing apoptosis. The results show that almost
all of the TUNEL-positive cells colocalized with a-SMA, sug-
gesting myoﬁbroblast apoptosis (Figure 12, EeG).
To determine the in vivo contribution of the SRF/MRTF
signaling pathway to PAI-1 production, we treated both
targeted type II AECe and bleomycin-injured mice with
CCG-203971 and collected bronchoalveolar lavage ﬂuid for
PAI-1 quantiﬁcation. In preliminary studies, we found no
difference in active PAI-1 levels in the bronchoalveolar
lavage ﬂuid of uninjured mice treated with or without
CCG-203971. Therefore, for our control group in these
experiments, we used an uninjured/untreated group. In the
bleomycin model, we observed a signiﬁcant decrease in the
mean active PAI-1 level after inhibition of the SRF/MRTF
pathway (Figure 13A). Similarly, inhibition of SRF/MRTF
after targeted type II AEC injury resulted in a signiﬁcant
decrease in the quantity of active PAI-1 (Figure 13B).Discussion
The accumulation and persistence of activated mesenchymal
cells is integral to the development of ﬁbrosis in the lung
and other organs.4,44 Myoﬁbroblasts have been morpho-
logically and functionally characterized by their expression
of organized stress ﬁbers that incorporate a-SMA and their
secretion of extracellular matrix constituents, including type
1 collagen and ﬁbronectin. The elimination of myoﬁbro-
blasts via apoptosis is crucial for the resolution of wound
repair and the restoration of tissue homeostasis after
injury.7,45 However, these cells characteristically display a
phenotype of apoptosis resistance, especially in the setting
of ongoing tissue ﬁbrosis.4,45 The central roles that myoﬁ-
broblast activation and survival play in the pathobiology of
ﬁbrosis highlight the attractiveness of these cells as targets
for antiﬁbrotic interventions.3,37 Based on the described role
that SRF/MRTF signaling plays in myoﬁbroblast activation,
our initial goal was to determine the efﬁcacy of targeting
this pathway as a therapeutic intervention for in vivo lung
ﬁbrosis. Indeed, we found that CCG-203971, a novel
nipecotic bis(amide) inhibitor of SRF/MRTF transcriptionalThe American Journal of Pathology - ajp.amjpathol.orgactivity, markedly attenuates lung ﬁbrosis in two comple-
mentary murine models. After deﬁning a crucial causal role
for SRF/MRTF in ﬁbrosis in vivo, our next goal was to
investigate potential mechanisms by which this signaling
pathway regulates ﬁbrosis beyond myoﬁbroblast differentia-
tion. Importantly, we found that this pathway plays previously
unrecognized roles in the regulation of PAI-1 production both
in vitro and in vivo, in the regulation of XIAP expression by
ﬁbroblasts, and in ﬁbroblast susceptibility to apoptosis.
Recent studies have shown that targeting SRF/MRTF
signaling in ﬁbroblasts derived from multiple organs,
including the skin and colon, blocks myoﬁbroblast differ-
entiation and collagen production induced by TGF-b1.16,20
As an initial step in our investigation, we found that
CCG-203971 blocked TGF-b1 induced expression of
a-SMA and ﬁbronectin in lung ﬁbroblasts at concentrations
consistent with those shown in skin and colon ﬁbroblasts.
Each of these proteins is crucial to myoﬁbroblast function,
as a-SMA expression confers cells with increased contractile
activity,6 whereas cellular ﬁbronectin is required for myoﬁ-
broblast differentiation and serves as a link between organized
stress ﬁbers and the pericellular matrix.32,46 Although there was
no clear effect on basal levels of a-SMA expression, blocking
SRF/MRTF signaling with CCG-203971 did suppress basal
levels of ﬁbronectin, suggesting that this pathway has a previ-
ously unrecognized regulatory role in ﬁbronectin homeostasis.
The inhibition of ﬁbroblast function by the targeting of
SRF/MRTF signaling was recently extended to an in vivo
murine model of skin ﬁbrosis induced by bleomycin, in
which CCG-203971 led to a signiﬁcant reduction in the
development of dermal ﬁbrosis.20 To investigate the efﬁcacy
of targeting this pathway with a therapeutic strategy in lung
ﬁbrosis, we used two distinct murine models (intratracheal
bleomycin and targeted type II AEC injury).28,36 In the
bleomycin model, we initiated the treatment during the
ﬁbrotic phase, and CCG-203971 administration was asso-
ciated with a rapid reversal of the injury-induced weight loss
and a signiﬁcant reduction in the severity of ﬁbrosis.
Importantly, CCG-203971 had no detrimental effect on
the weight of control mice. In the targeted type II AEC
injury model of ﬁbrosis, we similarly began treatment with981
Figure 12 Myoﬁbroblast apoptosis is increased in vivo after the
administration of CCG-203971 during the ﬁbroproliferative phase of lung
injury. Lung sections were analyzed for cell death by terminal deoxy-
nucleotidyl transferase dUTP nick end labeling (TUNEL) staining (red) 2
weeks after the instillation of intratracheal phosphate-buffered saline (A)
or bleomycin (Bleo) (B and C) and 3 days after the initiation of dimethyl
sulfoxide (B) or CCG-203971 (CCG971) (C). D: TUNEL-positive (pos) cells
were quantiﬁed in 10 random 400 ﬁelds by a blinded observer (K.K.K.).
E and F: Lungs from bleomycin-injured mice treated with CCG-203971 were
co-stained for TUNEL (E) and a-smooth muscle actin (SMA; green; F).
G: Merged images demonstrate colocalization of TUNEL and a-SMA. Data
are expressed as means  SEM. n Z 3 per group (D). *P < 0.05 versus
bleomycin alone.
Sisson et alCCG-203971 on day 11, such that there was limited overlap
between DT-mediated injury of the alveolar epithelium and
the drug administration. Although the effect of the drug
on weight loss in this model was not as dramatic as in
the bleomycin model, interference with the SRF/MRTF
pathway resulted in a signiﬁcant reduction inﬁbrosis. Of note,
the ﬁbrosis observed in this model is quite different from that
seen in the bleomycin model. Instead of distinct areas of
consolidation, the ﬁbrosis is diffuse in nature and is observed
as a more homogeneous thickening of alveolar interstitium,
consistent with the pattern described in our original publica-
tion using this model of ﬁbrosis.28 The demonstration of an
antiﬁbrotic effect of SRF/MRTF inhibition in two separate982models highlights the importance of this pathway in ﬁbro-
genesis while demonstrating that these effects are not model
dependent.36,37,47
Furthermore, our ﬁndings are consistent with those from
recent studies evaluating the role of Rho/SRF/MRTF
signaling in lung ﬁbrosis. For example, one report showed
evidence of increased Rho signaling in ﬁbroblastic foci from
IPF lung tissue and in ﬁbrotic murine lungs after intratracheal
bleomycin.13 In this same study, therapeutic administration
of the Rho-kinase inhibitor fasudil led to a signiﬁcant re-
duction in ﬁbrosis. Moreover, mice deﬁcient in MRTF-A had
signiﬁcantly decreased lung ﬁbrosis 28 days after bleomycin
administration. In a more recent study, noscapine, which
targets microtubule polymerization and blocks TGF-b1e
induced MRTF-A nuclear localization, was administered 7
days after bleomycin-induced injury and resulted in a sig-
niﬁcant reduction in lung collagen.48 Collectively, these
studies support a crucial role for Rho/SRF/MRTF signaling
in lung injury, repair, and ﬁbrosis. These ﬁndings are
consistent with those from prior studies showing that MRTF-
A null mice have decreased ﬁbrosis in the heart after
myocardial infarction or activation of the renineangiotensin
system and decreased renal ﬁbrosis in a model of diabetic
nephropathy.49,50
To investigate the mechanisms underlying the decrease in
lung ﬁbrosis attributable to SRF/MRTF inhibition, we
examined the impact of CCG-203971 administration on
myoﬁbroblast susceptibility to apoptosis. Clearance of
myoﬁbroblasts via apoptosis has been shown to be crucial
for normal tissue repair,3,45 and studies have demonstrated
that ﬁbrotic lung ﬁbroblasts, and normal lung ﬁbroblasts
exposed to TGF-b1, acquire an apoptosis-resistant pheno-
type in vitro.13,24,28,36,51,52 Furthermore, accumulating
in vivo evidence shows that the regulation of prosurvival
signaling can modulate lung ﬁbrosis in several different
murine models.35,53e58 Recent studies have shown that the
inhibition of Rho/Rho-kinase signaling decreases ﬁbroblast
expression of antiapoptotic BCL-2 family proteins and
promotes IPF lung ﬁbroblast apoptosis while decreasing lung
ﬁbrosis in vivo.13,19 To investigate the effect of targeting the
SRF/MRTF pathway on lung ﬁbroblast susceptibility to Fas-
mediated apoptosis, we used three distinct methods in two
normal lung ﬁbroblast cell lines and in normal and IPF
patientederived lung ﬁbroblasts. In each cell line and with
each method, we found that treatment with CCG-203971 led
to a signiﬁcantly enhanced apoptotic response to Fas acti-
vation. In contrast to the apoptosis-resistant phenotype of
normal and IPF ﬁbroblasts, murine ﬁbroblasts lacking
MRTF-A were sensitive to Fas-induced apoptosis in the
absence of CCG-203971. Of note, TGF-b1 treatment failed to
rescue ﬁbroblasts from apoptosis induced by Fas-activating
antibodies in the presence of CCG-203971, consistent with
the role of SRF/MRTF as a downstream mediator of the
antiapoptotic effects of TGF-b1.15 Importantly, CCG-203971
had a minimal effect on ﬁbroblast apoptosis in the absence of
the Fas-Ab.ajp.amjpathol.org - The American Journal of Pathology
Figure 13 CCG-203971 treatment decreases alveolar plasminogen acti-
vator inhibitor (PAI)-1 in murine models of lung injury and ﬁbrosis. Mice were
injured with bleomycin (A) or targeted type II alveolar epithelial cell (AEC)
injury (B), and CCG-203971 treatment was initiated on day 11. Bron-
choalveolar lavage ﬂuid was collected on day 21 after bleomycin injury and on
day 15 in the AEC-injury model. Levels of active PAI-1 were quantiﬁed by using
a carboxylated microsphereebased enzyme-linked immunosorbent assay.
Data are expressed as means  SEM. n Z 5, control group (A); n Z 9,
bleomycin-treated groups (A); nZ 5, all groups (B). *P < 0.05, **P < 0.01
versus controls; yP< 0.05 versus bleomycin or diphtheria toxin receptor (DTR)
mice treated with diphtheria toxin (DT). WT, wild type.
MRTF in Lung Fibrosis and Fibroblast ApoptosisThe ﬁndings from our in vitro experiments indicate that
the SRF/MRTF pathway regulates myoﬁbroblast suscepti-
bility to apoptosis, in part, through the expression of XIAP.
Members of the inhibitor of apoptosis protein family have
been shown to regulate resistance to apoptosis in normal
and IPF lung ﬁbroblasts.24,36,41,59,60 XIAP is the best
studied of the inhibitor of apoptosis protein family and is
the most likely to function as a direct caspase inhibitor
in vivo.61 XIAP expression is increased in the ﬁbroblast foci
of IPF tissue and in explanted myoﬁbroblasts from IPF
lungs.36,60 Moreover, XIAP expression in normal lung ﬁ-
broblasts is increased by TGF-b1 and the functional inhi-
bition of XIAP sensitizes normal and IPF lung ﬁbroblasts to
Fas-mediated apoptosis.36 Here, we show that the inhibition
of SRF/MRTF signaling with CCG-203971 completely
suppressed TGF-b1einduced up-regulation of XIAP, sug-
gesting one feasible mechanismwherebyMRTF contributes
to apoptosis resistance in ﬁbroblasts. Supporting the hy-
pothesis that sensitization of myoﬁbroblasts to apoptosis
might contribute to the reduction in ﬁbrosis observed in our
in vivo models, we found evidence of a statistically signif-
icant increase in myoﬁbroblast apoptosis in the lungs of
bleomycin-treated mice 3 days after the initiation of CCG-
203971 treatment.
A robust literature demonstrates the strong proﬁbrotic ef-
fect of PAI-1, and we have shown a crucial role for this
multifunctional protein in the pathogenesis of both bleomy-
cin and targeted type II AEC injuryeinduced ﬁbrosis.26,30,62
Although the ﬁndings from a previous study suggested that
TGF-b1einduced PAI-1 expression is independent of SRF/
MRTF-mediated transcription, our data strongly implicate
this pathway in the regulation of this proﬁbrotic molecule.15
Speciﬁcally, CCG-203971 treatment blocked TGF-b1e
mediated secretion of total and active PAI-1 into cell culture
supernatants. Additionally, we found that inhibition of SRF/
MRTF signiﬁcantly reduces PAI-1 levels in the alveolarThe American Journal of Pathology - ajp.amjpathol.orgcompartment of both bleomycin and targeted type II
AECeinjured mice. Although the precise mechanisms by
which PAI-1 promotes ﬁbrosis are unclear, this molecule has
been found to protect ﬁbroblasts from apoptosis induced by
plasmin while also inhibiting degradation of matrix ﬁbro-
nectin.40,63,64 Moreover, prior studies in vivo indicate that the
vitronectin-binding function of PAI-1 is crucial to its proﬁ-
brotic effect.30 Thus, the demonstration that CCG-203971
inhibits myoﬁbroblast secretion of PAI-1 in vitro and de-
creases levels of active PAI-1 in vivo support another
mechanism by which the SRF/MRTF signaling pathway
might impact lung ﬁbrosis.
Myoﬁbroblast differentiation and activation in response
to soluble and matrix-associated stimuli require Rho-
dependent polymerization of the actin cytoskeleton, allow-
ing for the nuclear localization of MRTF.14 In ﬁbroblasts,
nuclear localization of MRTF is induced by TGF-b1 and is
required for myoﬁbroblast differentiation and collagen
synthesis.15,18,49 The proﬁbrotic role of MRTF is not limited
to TGF-b1emediated signaling, however, as it is also
required for myoﬁbroblast differentiation and collagen
synthesis induced by lysophosphatidic acid and by mecha-
notransduction pathways activated by stiff matrix sub-
strates.13,25,65 This pathway is counter-regulated by known
antiﬁbrotic mediators. Speciﬁcally, the antiﬁbrotic eicosa-
noid prostaglandin E2 signals through the prostaglandin E
receptor 2 to prevent TGF-b1emediated myoﬁbroblast
differentiation and collagen production, to increase myoﬁ-
broblast susceptibility to Fas-mediated apoptosis, and to
decrease ﬁbroblast expression of the TGF-b1regulated in-
hibitor of apoptosis protein family members.36,41,59,60,66
Consistently, prostaglandin E2 has been shown to block
nuclear localization of MRTF.31 The ﬁndings from another
study showed that noscapine-mediated inhibition of myoﬁ-
broblast differentiation in vitro and lung ﬁbrosis in vivo are
mediated by prostaglandin E receptor 2.48
Fibrosis of the lungs and other organs is estimated to
contribute to up to 45% of deaths in developed countries,
highlighting the pressing need for antiﬁbrotic treatments.67
In diseases of the lung, ﬁbrosis is typically advanced at the
time of diagnosis. Promising results from recent clinical
trials show that the rate of progression of ﬁbrosis can be
slowed, but the potential to reverse ﬁbrotic changes in the
adult lung remains poorly understood.37,68,69 The ﬁndings
of our current study demonstrate that a novel compound
targeting the SRF/MRTF signaling, when initiated during
the ﬁbroproliferative phase of two distinct animal models,
can decrease the severity of lung ﬁbrosis and increase
myoﬁbroblast apoptosis in vivo while blocking myoﬁbro-
blast differentiation and enhancing myoﬁbroblast suscep-
tibility to apoptosis in vitro. Combined with studies
showing that IPF lung ﬁbroblasts have increased nuclear
localization of MRTF,13 these studies demonstrate a cen-
tral role for SRF/MRTF signaling in the pathogenesis of
lung ﬁbrosis, making this pathway an attractive therapeutic
target.983
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